Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Shares Drop 12 Percent

Shares in Bruker BioSciences declined 12 percent for the five-day trading period ended Tuesday. The firm's stock dropped steadily from closing at $5.43 last Wednesday to $4.75 at the close of trading on Tuesday, with trading volume unusually high over the last few days. The only news from the firm was a molecular diagnostics alliance announced on Tuesday (see Briefs).

Applied Biosystems, Molecular Devices, and Stratagene also lost more than 4 percent for the tracking period. Bio-Rad led gainers with a 5.2 percent rise in its stock, as the firm announced it had resumed settlement talks with Applera regarding a patent infringement case (see feature).

Overall, the BCW Index fell 1 percent this past week. The Nasdaq declined 1.9 percent, the Nasdaq Biotech Index dropped 1.7 percent, and the Dow Jones Industrial Average inched down .2 percent for the week.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Dec. 20, 2005)
Last Price
(Dec. 13, 2005)
% change
Agilent
A
34.82
35.98
-3.22
Applied Biosystems
ABI
26.27
27.57
-4.72
Beckman
BEC
57.04
57.22
-0.31
Bio-Rad
BIO
63.29
60.14
5.24
Bruker
BRKR
4.75
5.4
-12.04
Fisher Scientific
FSH
62.85
64.52
-2.59
GE
GE
35.54
35.47
0.20
Harvard Bio
HBIO
4.32
4.69
-7.89
Invitrogen
IVGN
66.95
66.56
0.59
Molecular Devices
MDCC
27.05
28.21
-4.11
PerkinElmer
PKI
23.1
23.4
-1.28
Qiagen
QGEN
11.68
11.67
0.09
Sigma
SIAL
63.52
65.2
-2.58
Stratagene
STGN
10.17
10.69
-4.86
Thermo
TMO
31.78
30.76
3.32
Waters
WAT
37.91
39.29
-3.51
BCW Index Average
35.07
35.42
-1.01
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.